We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Catalent Biologics, Moderna Therapeutics Collaborate

News   Oct 22, 2016

 
Catalent Biologics, Moderna Therapeutics Collaborate
 
 
 

RELATED ARTICLES

Compound Combo Shrinks Pancreatic Tumors in Mice Providing Rationale for Clinical Study

News

Scientists have identified a combination of two anti-cancer compounds that were able to shrink pancreatic tumors in mice – supporting the immediate evaluation of the drugs in a clinical trial.

READ MORE

A Change in Cell Logistics Helps Cancer Become Resistant

News

Researchers have discovered that breast cancers which had become resistant to hormone therapy have a molecular "advantage" that helps the cells successfully evade hormone therapies.

READ MORE

GW Pharmaceuticals Receives Positive NICE Recommendation for EPIDYOLEX (Cannabidiol)

News

GW Pharmaceuticals plc announces that two of its medicines, EPIDYOLEX (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by the UK’s National Institute for Health and Care Excellence (NICE) to receive routine reimbursement from NHS England.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE